This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muir, K. W. Search for Related Content PubMed PubMed Citation Articles by Muir, K. W. Related Collections Acute Stroke Syndromes Emergency treatment of Stroke Neuroprotectors

(Stroke. 2002;33:1545.)
© 2002 American Heart Association, Inc.

Original Contributions

Heterogeneity of Stroke Pathophysiology and Neuroprotective Clinical Trial Design

Keith W. Muir, MD, MRCP

From the University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland.

Correspondence to K.W. Muir, MD, South Glasgow University Hospital, NHS Trust, University Department of Neurology, Institute of Neurological Sciences, 1345 Govan Rd, Glasgow G51 4TF, Scotland. E-mail k.muir{at}clinmed.gla.ac.uk

Background and Purpose— Tissue substrates for action of neuroprotective agents may be absent in a significant proportion of strokes. Pathophysiological heterogeneity is a possible contributor to negative neuroprotective trials.

Methods— Stroke subtypes and their individual outcomes in neuroprotective trial control populations were used to derive models incorporating accuracy of clinical classification and probability of an ischemic penumbra. With the use of treatment effect sizes from successful trials (predominantly of reperfusion therapies), sample sizes for neuroprotective trials were calculated. The potential influence of altered recruitment strategies was explored.

Results— The proportion of informative patients in 2 large neuroprotective trials was probably only 27% to 30%. Optimistically, this proportion may be 50%; pessimistically, it may be only 17%. These figures necessitate a sample size of 3700 to 4500 subjects per group; at best, 1800 to 2200 are needed per group with optimistic assumptions about treatment effect. Strategies to enhance the proportion with tissue substrate for neuroprotection could reduce sample size to 500 per group and simultaneously reduce the total number of patients screened compared with inclusive trials.

Conclusions— Population heterogeneity alone may be sufficient to explain negative neuroprotective trials because even in the largest trials to date sample size is inadequate to detect effect size equivalent to those with thrombolysis, and it is possible that they have been severely underpowered. Reliable trials with inclusive entry criteria may be too large to be commercially feasible for novel compounds. Both sample size and total number of patients needing to be screened should be reduced by restricting entry to patients more likely to have a tissue target.

Key Words: controlled clinical trials • neuroprotection

This article has been cited by other articles:

				K. A. Dani, M. T. McCormick, and K. W. Muir Brain Lesion Volume and Capacity for Consent in Stroke Trials: Potential Regulatory Barriers to the Use of Surrogate Markers Stroke, August 1, 2008; 39(8): 2336 - 2340. [Abstract] [Full Text] [PDF]

				M. Ali, P. M.W. Bath, J. Curram, S. M. Davis, H.-C. Diener, G. A. Donnan, M. Fisher, B. A. Gregson, J. Grotta, W. Hacke, et al. The Virtual International Stroke Trials Archive Stroke, June 1, 2007; 38(6): 1905 - 1910. [Abstract] [Full Text] [PDF]

				H C A Emsley, C J Smith, R F Georgiou, A Vail, S J Hopkins, N J Rothwell, P J Tyrrell, and for the IL-1ra in Acute Stroke Investigators A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients J. Neurol. Neurosurg. Psychiatry, October 1, 2005; 76(10): 1366 - 1372. [Abstract] [Full Text] [PDF]

				R. R. Ratan, A. Siddiq, L. Aminova, P. S. Lange, B. Langley, I. Ayoub, J. Gensert, and J. Chavez Translation of Ischemic Preconditioning to the Patient: Prolyl Hydroxylase Inhibition and Hypoxia Inducible Factor-1 as Novel Targets for Stroke Therapy Stroke, November 1, 2004; 35(11_suppl_1): 2687 - 2689. [Abstract] [Full Text] [PDF]

				C. J. Weir, M. Kaste, K. R. Lees, and for the Glycine Antagonist in Neuroprotection Int Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy Stroke, September 1, 2004; 35(9): 2111 - 2116. [Abstract] [Full Text] [PDF]

				J. M. Silakova, J. A. Hewett, and S. J. Hewett Naproxen Reduces Excitotoxic Neurodegeneration in Vivo with an Extended Therapeutic Window J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1060 - 1066. [Abstract] [Full Text] [PDF]

				P. A. Lapchak and J. A. Zivin Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits: Synergism With Low-Dose Tissue Plasminogen Activator Stroke, August 1, 2003; 34(8): 2013 - 2018. [Abstract] [Full Text] [PDF]

				S J Allder, A R Moody, A L Martel, P S Morgan, G S Delay, J R Gladman, and G G Lennox Differences in the diagnostic accuracy of acute stroke clinical subtypes defined by multimodal magnetic resonance imaging J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 886 - 888. [Abstract] [Full Text] [PDF]

				M. Fisher Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3 Stroke, June 1, 2003; 34(6): 1539 - 1546. [Abstract] [Full Text] [PDF]

				A. J. Furlan Acute Stroke Trials: Strengthening the Underpowered Stroke, June 1, 2002; 33(6): 1450 - 1451. [Full Text] [PDF]